<pmc-articleset>
  <article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4">
    <!--The publisher of this article does not allow downloading of the full text in XML form.-->
    <front>
      <journal-meta>
        <journal-id journal-id-type="nlm-ta">JCO Precis Oncol</journal-id>
        <journal-id journal-id-type="iso-abbrev">JCO Precis Oncol</journal-id>
        <journal-id journal-id-type="pmc-domain-id">3882</journal-id>
        <journal-id journal-id-type="pmc-domain">jcopo</journal-id>
        <journal-id journal-id-type="publisher-id">PO</journal-id>
        <journal-title-group>
          <journal-title>JCO Precision Oncology</journal-title>
        </journal-title-group>
        <issn pub-type="epub">2473-4284</issn>
        <publisher>
          <publisher-name>American Society of Clinical Oncology</publisher-name>
        </publisher>
      </journal-meta>
      <article-meta>
        <article-id pub-id-type="pmcid">PMC10309566</article-id>
        <article-id pub-id-type="pmcid-ver">PMC10309566.1</article-id>
        <article-id pub-id-type="pmcaid">10309566</article-id>
        <article-id pub-id-type="pmcaiid">10309566</article-id>
        <article-id pub-id-type="pmid">37315267</article-id>
        <article-id pub-id-type="doi">10.1200/PO.22.00705</article-id>
        <article-id pub-id-type="publisher-id">PO.22.00705</article-id>
        <article-version article-version-type="pmc-version">1</article-version>
        <article-categories>
          <subj-group subj-group-type="heading">
            <subject>ORIGINAL REPORTS</subject>
            <subj-group>
              <subject>Cancer Genomics</subject>
            </subj-group>
          </subj-group>
        </article-categories>
        <title-group>
          <article-title>Extremity Rhabdomyosarcoma—An Integrated Clinicopathologic and Genomic Study to Improve Risk Stratification</article-title>
        </title-group>
        <contrib-group>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>de Traux de Wardin</surname>
              <given-names initials="H">Henry</given-names>
            </name>
            <degrees>MD</degrees>
            <xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref>
          </contrib>
          <contrib contrib-type="author">
            <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-4638-9835</contrib-id>
            <name name-style="western">
              <surname>Xu</surname>
              <given-names initials="B">Bin</given-names>
            </name>
            <degrees>MD, PhD</degrees>
            <xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref>
          </contrib>
          <contrib contrib-type="author">
            <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-1139-2914</contrib-id>
            <name name-style="western">
              <surname>Dermawan</surname>
              <given-names initials="JK">Josephine K.</given-names>
            </name>
            <degrees>MD, PhD</degrees>
            <xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Smith</surname>
              <given-names initials="MH">Mariel H.</given-names>
            </name>
            <degrees>MD</degrees>
            <xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref>
          </contrib>
          <contrib contrib-type="author">
            <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-5234-4134</contrib-id>
            <name name-style="western">
              <surname>Wolden</surname>
              <given-names initials="SL">Suzanne L.</given-names>
            </name>
            <degrees>MD</degrees>
            <xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref>
          </contrib>
          <contrib contrib-type="author">
            <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-9717-8205</contrib-id>
            <name name-style="western">
              <surname>Antonescu</surname>
              <given-names initials="CR">Cristina R.</given-names>
            </name>
            <degrees>MD</degrees>
            <xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref>
          </contrib>
          <contrib contrib-type="author" corresp="yes">
            <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-0724-8263</contrib-id>
            <name name-style="western">
              <surname>Wexler</surname>
              <given-names initials="LH">Leonard H.</given-names>
            </name>
            <degrees>MD</degrees>
            <xref rid="aff4" ref-type="aff">
<sup>4</sup>
</xref>
            <xref rid="cor1" ref-type="corresp"/>
            <xref rid="con1" ref-type="fn"/>
          </contrib>
          <aff id="aff1"><label><sup>1</sup></label>Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY</aff>
          <aff id="aff2"><label><sup>2</sup></label>Pediatric Hematology/Oncology, Massachusetts General Hospital for Children, Boston, MA</aff>
          <aff id="aff3"><label><sup>3</sup></label>Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY</aff>
          <aff id="aff4"><label><sup>4</sup></label>Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY</aff>
        </contrib-group>
        <author-notes>
          <corresp id="cor1">Leonard H. Wexler, MD, Department of Pediatrics, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10065; Twitter: @mskcancercenter; e-mail: <email>wexlerl@mskcc.org</email>.</corresp>
        </author-notes>
        <pub-date pub-type="collection">
          <year>2023</year>
        </pub-date>
        <pub-date pub-type="epub">
          <day>14</day>
          <month>6</month>
          <year>2023</year>
        </pub-date>
        <volume>7</volume>
        <issue>1</issue>
        <issue-id pub-id-type="pmc-issue-id">429012</issue-id>
        <elocation-id>e2200705</elocation-id>
        <history>
          <date date-type="received">
            <day>23</day>
            <month>12</month>
            <year>2022</year>
          </date>
          <date date-type="rev-recd">
            <day>30</day>
            <month>3</month>
            <year>2023</year>
          </date>
          <date date-type="accepted">
            <day>8</day>
            <month>5</month>
            <year>2023</year>
          </date>
        </history>
        <pub-history>
          <event event-type="pmc-release">
            <date>
              <day>14</day>
              <month>06</month>
              <year>2024</year>
            </date>
          </event>
          <event event-type="pmc-live">
            <date>
              <day>14</day>
              <month>06</month>
              <year>2024</year>
            </date>
          </event>
          <event event-type="pmc-last-change">
            <date iso-8601-date="2024-09-26 14:25:36.953">
              <day>26</day>
              <month>09</month>
              <year>2024</year>
            </date>
          </event>
        </pub-history>
        <permissions>
          <copyright-statement>© 2023 by American Society of Clinical Oncology</copyright-statement>
          <copyright-year>2023</copyright-year>
          <copyright-holder>American Society of Clinical Oncology</copyright-holder>
        </permissions>
        <self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="po-7-e2200705.pdf"/>
        <self-uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="po-7-e2200705.pdf"/>
        <abstract>
          <sec>
            <title>PURPOSE</title>
            <p>Extremity rhabdomyosarcoma (RMS) is associated with a very poor outcome compared with other sites, mainly because of its high incidence of alveolar histology and regional lymph node involvement. To better define prognostic markers in this clinical subset, we investigated our experience of 61 patients with extremity RMS treated at our tertiary cancer center for the past 2 decades.</p>
          </sec>
          <sec>
            <title>PATIENTS AND METHODS</title>
            <p>The patients had a median age of 8 years at diagnosis, equal gender distribution, and two-thirds occurred in the lower extremity. Most (85%) patients had <italic toggle="yes">FOXO1</italic> fusion–positive alveolar RMS (ARMS), with 70% having a <italic toggle="yes">PAX3::FOXO1</italic> transcript. Remaining were seven patients with fusion-negative embryonal RMS (ERMS) and two with <italic toggle="yes">MYOD1-</italic>mutant spindle cell/sclerosing RMS (SRMS). In 40% of the patients, material was available for DNA-based targeted sequencing using MSK-IMPACT cancer gene panel.</p>
          </sec>
          <sec>
            <title>RESULTS</title>
            <p>One-third of patients presented with localized disease at diagnosis while the remaining had regional nodal (18%) or distant metastases (51%). Metastatic disease, high-risk group, and age 10 years or older significantly affected the overall survival (OS; hazard ratio [HR], 2.68 [<italic toggle="yes">P</italic> = .004], 2.78 [<italic toggle="yes">P</italic> = .010] and 2.26 [<italic toggle="yes">P =</italic> .034], respectively). Although the presence of metastatic disease had a dismal impact on 5-year EFS and OS (19% and 29%, respectively), nodal involvement had a comparatively lower impact on 5-year EFS and 5-year OS (43% and 66%, respectively). <italic toggle="yes">PAX3::FOXO1</italic> ARMS had worse prognosis and afflicted older children compared with <italic toggle="yes">PAX7::FOXO1</italic> (HR = 3.45, <italic toggle="yes">P =</italic> .016). The most common events in the ARMS group included <italic toggle="yes">MED12</italic> alterations, <italic toggle="yes">CDK4</italic> amplifications, and <italic toggle="yes">CDKN2A</italic> deletions (8%-17%). The latter two abnormalities were mutually exclusive, enriched for acral and high-risk lesions, and correlated with poor outcome on OS (<italic toggle="yes">P</italic> = .02).</p>
          </sec>
          <sec>
            <title>CONCLUSION</title>
            <p>Our data provide rationale for considering the integration of molecular abnormalities to refine risk stratification in extremity RMS.</p>
          </sec>
        </abstract>
        <abstract abstract-type="teaser">
          <p>A clinical and genomic investigation of extremity RMS shows that CDKN2A and CDK4 alterations are associated with poor OS.</p>
        </abstract>
        <counts>
          <fig-count count="6"/>
          <table-count count="6"/>
          <equation-count count="0"/>
          <ref-count count="36"/>
          <page-count count="0"/>
        </counts>
        <custom-meta-group>
          <custom-meta>
            <meta-name>pmc-status-qastatus</meta-name>
            <meta-value>0</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-status-live</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-status-embargo</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-status-released</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-open-access</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-olf</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-manuscript</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-legally-suppressed</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-has-pdf</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-has-supplement</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-pdf-only</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-suppress-copyright</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-is-real-version</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-is-scanned-article</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-preprint</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-in-epmc</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
        </custom-meta-group>
      </article-meta>
    </front>
  </article>
</pmc-articleset>
